Glaxo Antibody Treatment Works on Omicron Mutations in Study
- Therapy stood up against 37 mutations after in-vitro trial
- Shares of co-developer Vir Biotechnology rise in pre-market
A dose of Sotrovimab Covid-19 antibody treatment
Source: GlaxoSmithKline Plc
This article is for subscribers only.
GlaxoSmithKline Plc said research shows its Covid-19 antibody treatment is effective against the full combination of mutations in the new omicron variant.
Tests done in-vitro against a pseudo-virus that recreates a synthesized version of omicron showed that sotrovimab, Glaxo’s antibody treatment, stands up to all mutations in the spike protein of the omicron variant and not just the key mutations, the drugmaker said in a statement Tuesday. The tests included all 37 mutations identified to-date in the spike protein.